Bio-Rad Laboratories (BIO) Equity Average (2010 - 2026)

Bio-Rad Laboratories (BIO) has 17 years of Equity Average data on file, last reported at $7.2 billion in Q1 2026.

• Equity Average for Q1 2026 came in at $7.2 billion, up 7.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.2 billion (up 7.97% YoY), and the FY2025 annual result was $7.0 billion, down 8.41% from the prior year.
• Equity Average rose to $7.2 billion in Q1 2026 per BIO's latest filing, from $7.1 billion in the prior quarter.
• Over five years, Equity Average peaked at $11.9 billion in Q1 2022 and troughed at $6.6 billion in Q1 2025.
• A 5-year average of $8.3 billion and a median of $8.4 billion in 2023 frame the typical range for Equity Average.
• On a YoY basis, Equity Average climbed as much as 16.54% in 2022 and fell as far as 37.65% in 2022.
• A 5-year view of Equity Average shows it stood at $9.0 billion in 2022, then slipped by 5.17% to $8.6 billion in 2023, then dropped by 18.07% to $7.0 billion in 2024, then advanced by 0.95% to $7.1 billion in 2025, then increased by 0.81% to $7.2 billion in 2026.
• Business Quant data shows BIO's Equity Average at $7.2 billion in Q1 2026, $7.1 billion in Q4 2025, and $6.9 billion in Q3 2025.